schliessen

Filtern

 

Bibliotheken

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience

Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. A retrospective review at MD Anderson Ca... Full description

Journal Title: The journal of clinical endocrinology and metabolism 2015, Vol.100 (1), p.E77-E81
Main Author: Dadu, Ramona
Other Authors: Shah, Komal , Busaidy, Naifa L , Waguespack, Steven G , Habra, Mouhammad A , Ying, Anita K , Hu, Mimi I , Bassett, Roland , Jimenez, Camilo , Sherman, Steven I , Cabanillas, Maria E
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: United States
ID: EISSN: 1945-7197
Link: https://www.ncbi.nlm.nih.gov/pubmed/25353071
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1643146425
title: Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
format: Article
creator:
  • Dadu, Ramona
  • Shah, Komal
  • Busaidy, Naifa L
  • Waguespack, Steven G
  • Habra, Mouhammad A
  • Ying, Anita K
  • Hu, Mimi I
  • Bassett, Roland
  • Jimenez, Camilo
  • Sherman, Steven I
  • Cabanillas, Maria E
subjects:
  • Aged
  • Antineoplastic Agents - adverse effects
  • Antineoplastic Agents - therapeutic use
  • Carcinoma - drug therapy
  • Carcinoma - genetics
  • Carcinoma - pathology
  • Carcinoma, Papillary
  • Female
  • Humans
  • Indoles - adverse effects
  • Indoles - therapeutic use
  • Male
  • Middle Aged
  • Off-Label Use
  • Protein Kinase Inhibitors - adverse effects
  • Protein Kinase Inhibitors - therapeutic use
  • Proto-Oncogene Proteins B-raf - genetics
  • Retrospective Studies
  • Sulfonamides - adverse effects
  • Sulfonamides - therapeutic use
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms - drug therapy
  • Thyroid Neoplasms - genetics
  • Thyroid Neoplasms - pathology
  • Treatment Outcome
  • Vemurafenib
ispartof: The journal of clinical endocrinology and metabolism, 2015, Vol.100 (1), p.E77-E81
description: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. A retrospective review at MD Anderson Cancer Center. The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. We identified 17 patients with advanced PTC harboring the BRAF(V600E) mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
language: eng
source:
identifier: EISSN: 1945-7197
fulltext: no_fulltext
issn:
  • 1945-7197
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6804223
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_proquest_miscellaneous_1643146425
sourceformatXML
sourcesystemPC
sourcerecordid1643146425
originalsourceidFETCH-LOGICAL-c245t-8c77a22c38e80aec6a9b4b14c66d2d47d8248589e59a6e82373b2692394a65e20
addsrcrecordideNo1kUtv2zAQhIkCReImvfUc8Jge5JAUSUm9uY7zABwECJpcCYpawTRkUiVpJ_4p-beh8zgNsPthFjuD0C9KppRRcrE2U0YoLxjj8hua0IaLoqJNdYx-xLgmecVFeYSOmShFSSo6Qa-LvrdGmz3WrsPJDxB0aweb9tj3eAebbdA9ONti6_CokwWXIn62aYX_Psyuzp8kIYvfxeijTXYHGRntMOiwx2m1D9522GhnIPzBd9PLKZ65DkL0Ds_fp3ie7bL4vseDbmHA8DJCyEcMnKLvvR4i_PzUE_R4tfg3vymW99e389myMIyLVNSmqjRjpqyhJhqM1E3LW8qNlB3reNXVjNeibkA0WkLNyqpsmWxY2XAtBTBygs4_fMfg_28hJrWx0UB-woHfRkUlLymXnImMnn2i23YDnRqD3eRX1VecGWAfgAk-xgC9Mjbl0LxLQdtBUaIOPam1UYee1KEn8gZwDYVc
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1643146425
display
typearticle
titleEfficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
creatorDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
creatorcontribDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
descriptionVemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. A retrospective review at MD Anderson Cancer Center. The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. We identified 17 patients with advanced PTC harboring the BRAF(V600E) mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
identifier
0EISSN: 1945-7197
1DOI: 10.1210/jc.2014-2246
2PMID: 25353071
languageeng
publisherUnited States
subjectAged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma - drug therapy ; Carcinoma - genetics ; Carcinoma - pathology ; Carcinoma, Papillary ; Female ; Humans ; Indoles - adverse effects ; Indoles - therapeutic use ; Male ; Middle Aged ; Off-Label Use ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Proto-Oncogene Proteins B-raf - genetics ; Retrospective Studies ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Thyroid Cancer, Papillary ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - pathology ; Treatment Outcome ; Vemurafenib
ispartofThe journal of clinical endocrinology and metabolism, 2015, Vol.100 (1), p.E77-E81
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-c245t-8c77a22c38e80aec6a9b4b14c66d2d47d8248589e59a6e82373b2692394a65e20
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25353071$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
title
0Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
1The journal of clinical endocrinology and metabolism
addtitleJ Clin Endocrinol Metab
descriptionVemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. A retrospective review at MD Anderson Cancer Center. The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. We identified 17 patients with advanced PTC harboring the BRAF(V600E) mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
subject
0Aged
1Antineoplastic Agents - adverse effects
2Antineoplastic Agents - therapeutic use
3Carcinoma - drug therapy
4Carcinoma - genetics
5Carcinoma - pathology
6Carcinoma, Papillary
7Female
8Humans
9Indoles - adverse effects
10Indoles - therapeutic use
11Male
12Middle Aged
13Off-Label Use
14Protein Kinase Inhibitors - adverse effects
15Protein Kinase Inhibitors - therapeutic use
16Proto-Oncogene Proteins B-raf - genetics
17Retrospective Studies
18Sulfonamides - adverse effects
19Sulfonamides - therapeutic use
20Thyroid Cancer, Papillary
21Thyroid Neoplasms - drug therapy
22Thyroid Neoplasms - genetics
23Thyroid Neoplasms - pathology
24Treatment Outcome
25Vemurafenib
issn1945-7197
fulltextfalse
rsrctypearticle
creationdate2015
recordtypearticle
recordideNo1kUtv2zAQhIkCReImvfUc8Jge5JAUSUm9uY7zABwECJpcCYpawTRkUiVpJ_4p-beh8zgNsPthFjuD0C9KppRRcrE2U0YoLxjj8hua0IaLoqJNdYx-xLgmecVFeYSOmShFSSo6Qa-LvrdGmz3WrsPJDxB0aweb9tj3eAebbdA9ONti6_CokwWXIn62aYX_Psyuzp8kIYvfxeijTXYHGRntMOiwx2m1D9522GhnIPzBd9PLKZ65DkL0Ds_fp3ie7bL4vseDbmHA8DJCyEcMnKLvvR4i_PzUE_R4tfg3vymW99e389myMIyLVNSmqjRjpqyhJhqM1E3LW8qNlB3reNXVjNeibkA0WkLNyqpsmWxY2XAtBTBygs4_fMfg_28hJrWx0UB-woHfRkUlLymXnImMnn2i23YDnRqD3eRX1VecGWAfgAk-xgC9Mjbl0LxLQdtBUaIOPam1UYee1KEn8gZwDYVc
startdate201501
enddate201501
creator
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
67X8
sort
creationdate201501
titleEfficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
authorDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c245t-8c77a22c38e80aec6a9b4b14c66d2d47d8248589e59a6e82373b2692394a65e20
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Aged
1Antineoplastic Agents - adverse effects
2Antineoplastic Agents - therapeutic use
3Carcinoma - drug therapy
4Carcinoma - genetics
5Carcinoma - pathology
6Carcinoma, Papillary
7Female
8Humans
9Indoles - adverse effects
10Indoles - therapeutic use
11Male
12Middle Aged
13Off-Label Use
14Protein Kinase Inhibitors - adverse effects
15Protein Kinase Inhibitors - therapeutic use
16Proto-Oncogene Proteins B-raf - genetics
17Retrospective Studies
18Sulfonamides - adverse effects
19Sulfonamides - therapeutic use
20Thyroid Cancer, Papillary
21Thyroid Neoplasms - drug therapy
22Thyroid Neoplasms - genetics
23Thyroid Neoplasms - pathology
24Treatment Outcome
25Vemurafenib
toplevelpeer_reviewed
creatorcontrib
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6MEDLINE - Academic
jtitleThe journal of clinical endocrinology and metabolism
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
formatjournal
genrearticle
ristypeJOUR
atitleEfficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
jtitleThe journal of clinical endocrinology and metabolism
addtitleJ Clin Endocrinol Metab
date2015-01
risdate2015
volume100
issue1
spageE77
epageE81
pagesE77-E81
eissn1945-7197
abstractVemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. A retrospective review at MD Anderson Cancer Center. The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. We identified 17 patients with advanced PTC harboring the BRAF(V600E) mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
copUnited States
pmid25353071
doi10.1210/jc.2014-2246
oafree_for_read